Growing interest in living longer, healthier lives is driving the expansion of the global longevity market. At Dittmar & Indrenius’ Is Ageing Good Business? event, experts discussed the science, consumer demand, investment landscape and commercial opportunities shaping the healthtech sector.
Ahead of Slush, one of the world’s leading startup events, Dittmar & Indrenius hosted the side event Is Ageing Good Business? The event attracted a full house keen to explore the scientific and commercial potential of this rapidly growing sector. Following opening remarks by Dittmar & Indrenius Partners Anna Haapanen and Juli Mansnérus, Isak Rautio, Founder and Host of Futucast, moderated a panel discussion.
According to Rautio, longevity, the art and science of living as long and as healthily as possible, has attracted increasing attention in recent years. While extending healthy lifespans has always been a concern in medicine, consumers are now taking a growing interest in the subject. This is partly due to podcasts exploring longevity and public figures such as biohacker Bryan Johnson, whose motto is “Don’t die”.
According to Jani Tikkanen, MD and Adjunct Professor, the longevity debate encompasses a wide range of ideas. Some are highly experimental or simply nonsense, while others are genuinely worth exploring. The arrival of new medicines, including GLP-1 receptor agonists, has made the subject more accessible and broadened the debate. Various health-related devices are also becoming increasingly popular.
“Our western lifestyle makes staying healthy more difficult. We eat constantly and do not move enough. This is a major challenge and will not be easy to solve. I hope we will become better at addressing it,” Tikkanen said.
Tikkanen reminded the audience that the longevity business is full of solutions that promise to be deceptively simple. People may, for example, be encouraged to take supplements or adopt practices that are not supported by scientific evidence.
“There are many theories and a lot of bullshit in this discussion. You can recognise someone whose claims are not based on science by their tendency to offer absolute truths about everything. A science-based expert, by contrast, is prepared to say ‘I don’t know’ when asked a difficult question.”
Consumers are driving the prevention market
Antti Kangas, Founder and CTO of Nightingale Health, discussed the challenges of preventive healthcare. The fundamental difficulty is that the costs are incurred today, while the benefits may not become apparent for decades.
“Longevity is making people more aware of their health and more willing to pay. Consumers are driving preventive healthcare and the adoption of new solutions. Investing in longevity is no longer regarded as something strange.”
According to Kangas, the greatest business opportunities lie in solutions that consumers are willing to pay for. Over time, consumer demand can also influence policy. When consumers lead the way, practices may eventually begin to change at the national level as well.
Nightingale Health has developed a blood test that can be used to assess the risk of major chronic diseases.
“It is a blood test that we originally developed for medical research and now it’s being used in clinics nationwide. It has a strong scientific foundation. Longevity clinics around the world are interested in it, but also public healthcare: In Finland, pilots using the test are under way in two wellbeing services counties, Eloisa and Siun sote.”
Despite growing consumer interest, Nightingale Health has chosen not to enter the consumer market.
“Building a consumer business is demanding, and I have great respect for those who do it. We see greater opportunities for ourselves as a provider empowering a wide range of health companies and platforms with our technology.”
Two very different longevity markets
Anders Carlberg, Senior Partner at Dittmar & Indrenius, said that investment in longevity companies continues to grow. Investors are becoming increasingly specialised, and some now have dedicated longevity teams.
Business models in the sector can broadly be divided into two categories: lifestyle and pharmaceuticals. In relation to the lifestyle market, behavioral and statistical companies focus on the fact that up to 80% of chronic disease risk is driven by modifiable everyday behaviors such as sleep, diet, exercise and metabolic choices. Barriers to market entry are lower, and companies can begin generating revenue more quickly. The investment horizon for such digital longevity and behavioural tech companies is 5-7 years.
The pharmaceutical market is very different, with product development typically taking between five and seven years. One of the challenges facing the longevity sector is that living longer is not a disease. Securing regulatory approval or finding a payer for a medicine intended to extend life is therefore complicated. The investment horizon for longevity pharma ventures is 10-15 years.
The panel also discussed access to funding in Finland. Although Finland is a small country, early-stage seed funding is relatively easy to secure.
“The problem is that we do not have a functioning domestic market, and the healthcare system is not good at purchasing new solutions. We need to make the domestic market work,” Tikkanen said.
Kangas agreed that Finland’s consumer market is small and that introducing innovations into the Finnish public sector is difficult. Innovations must therefore be designed with international markets in mind from the outset.
Nevertheless, the panellists identified several strengths that work in Finland’s favour, including its biobanks, healthcare data in digital form, strong ecosystem and testbeds.
Rautio also challenged the panellists to reveal how long they themselves would like to live. They all hoped to reach around 100 years of age, provided they could do so happily and in good health.
Text: Anna Niemelä | Pictures: Jussi Helttunen
“
Antti Kangas, Founder and CTO of Nightingale Health


